An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

R. de Boer1* Y. Humblet2 J. Wolf3 L. Nogová3 K. Ruffert4 T. Milenkova5 R. Smith5 A. Godwood6 and J. Vansteenkiste7

首页> 外文期刊>Annals of Oncology >An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

【24h】

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

机译：范德他尼联合培美曲塞的开放标签研究在先前治疗的非小细胞肺癌患者中的应用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The safety and tolerability of vandetanib plus pemetrexed was assessed in patients with advanced non-small-cell lung cancer (NSCLC).

机译：背景：Vandetanib（ZACTIMA™; ZD6474）是一种每日一次的血管内皮生长因子受体和表皮生长因子受体信号传导的口服抑制剂。在晚期非小细胞肺癌（NSCLC）患者中评估了vandetanib加pemetrexed的安全性和耐受性。

著录项

来源
《Annals of Oncology》 |2009年第3期|p.486-491|共6页
作者
R. de Boer1* Y. Humblet2 J. Wolf3 L. Nogová3 K. Ruffert4 T. Milenkova5 R. Smith5 A. Godwood6 and J. Vansteenkiste7;
展开▼
作者单位

1Department of Medical Oncology, Western Hospital, Melbourne, Australia 2Department of Medical Oncology, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium 3Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne 4Clinic and General Practice of Internal Medicine/Hematology/Oncology, Jena, Germany 5AstraZeneca, Alderley Park, Cheshire 6AstraZeneca, Charnwood, Leicestershire, UK 7University Hospital Leuven, Leuven, Belgium;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. [J] . de Boer R, Humblet Y, Wolf J, Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第3期

机译：凡德他尼联合培美曲塞的开放标签研究在先前治疗的非小细胞肺癌患者中进行。
2. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. [J] . Patel JD, Bonomi P, Socinski MA, Clinical lung cancer . 2009,第4期

机译：突破性研究的治疗原理和研究设计：培美曲塞/卡铂/贝伐单抗的随机，开放标签III期研究，然后进行培美曲塞/贝伐单抗与紫杉醇/卡铂/贝伐单抗的维持治疗，对IIIB或IV期非鳞状非IV期患者进行贝伐珠单抗治疗-小细胞肺癌。
3. A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-Small-Cell Lung Cancer [J] . Peter M. Ellis, Quincy S. Chu, Natasha Leighl, Clinical lung cancer . 2013,第1期

机译：先前治疗的非小细胞肺癌患者中静脉BI 2536联合培美曲塞的I期开放标签剂量升级研究
4. The impact of the type of resection on survival in patients with N1 non-small-cell lung cancers [C] . Umit Aydogmus, Levent Cansever, Yasar Sonmezoglu, 21st international conference on screening for lung cancer . 2009

机译：切除类型对N1非小细胞肺癌患者生存的影响
5. The effectiveness of chemoradiation for stage III non-small-cell lung cancer patients at the Kingston Regional Cancer Center (Ontario). [D] . Sinclair, Suzanne Marie. 2003

机译：金斯敦地区癌症中心（安大略省）对III期非小细胞肺癌患者进行化学放射治疗的有效性。
6. 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer [O] . Wolfgang Schuette, Claus-Peter Schneider, Walburga Engel-Riedel, 2017

机译：65Plus：贝伐单抗联合培美曲塞或培美曲塞/卡铂作为晚期或复发性非鳞状非小细胞肺癌患者的一线治疗的开放标签研究
7. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13 [O] . Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, 2019

机译：将Pemetrexed Plus顺铂进行随机开放标签的II次研究，然后通过单独的表皮生长因子受体（EGFR） - 富富毒素激酶抑制剂失败后单独维持Pemetrexed与培养型培养型培养型培养基患者： KCSG-LU12-13

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅